These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 31145074)

  • 1. Pembrolizumab-Induced Alopecia Areata.
    Elshimy N; Blakeway E; Mitra A
    Skinmed; 2019; 17(2):142-143. PubMed ID: 31145074
    [No Abstract]   [Full Text] [Related]  

  • 2. PD-1 inhibitor induced alopecia areata.
    Guidry J; Brown M; Medina T
    Dermatol Online J; 2018 Dec; 24(12):. PubMed ID: 30677804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute localised exanthematous pustulosis secondary to pembrolizumab.
    Wang CY; Khoo C; McCormack CJ; Xu W; Pan Y
    Australas J Dermatol; 2017 Nov; 58(4):322-323. PubMed ID: 28691194
    [No Abstract]   [Full Text] [Related]  

  • 4. Delayed skin toxicity associated with pembrolizumab therapy for metastatic melanoma.
    Arianayagam S; Ieremia E; Matin RN
    Eur J Dermatol; 2019 Jun; 29(3):349-351. PubMed ID: 31389799
    [No Abstract]   [Full Text] [Related]  

  • 5. Rituximab in the treatment of pembrolizumab-induced myasthenia gravis.
    Crusz SM; Radunovic A; Shepherd S; Shah S; Newey V; Phillips M; Lim L; Powles T; Szlosarek PW; Shamash J; Rashid S
    Eur J Cancer; 2018 Oct; 102():49-51. PubMed ID: 30138772
    [No Abstract]   [Full Text] [Related]  

  • 6. Remote-onset alopecia areata attributed to ipilimumab.
    Pearson DR; Lewis K; Alkousakis T
    Cutis; 2019 Dec; 104(6):E25-E27. PubMed ID: 31939941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Refractory myasthenia gravis exacerbation triggered By pembrolizumab.
    Earl DE; Loochtan AI; Bedlack RS
    Muscle Nerve; 2018 Apr; 57(4):E120-E121. PubMed ID: 29193151
    [No Abstract]   [Full Text] [Related]  

  • 8. Lupus-like cutaneous reaction following pembrolizumab: An immune-related adverse event associated with anti-PD-1 therapy.
    Shao K; McGettigan S; Elenitsas R; Chu EY
    J Cutan Pathol; 2018 Jan; 45(1):74-77. PubMed ID: 29028121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bullous pemphigoid induced by pembrolizumab in a patient with advanced melanoma expressing collagen XVII.
    Wada N; Uchi H; Furue M
    J Dermatol; 2017 Oct; 44(10):e240-e241. PubMed ID: 28677843
    [No Abstract]   [Full Text] [Related]  

  • 10. Cutaneous Eruption Secondary to Immunotherapy for Metastatic Melanoma Limited to Sites of Locoregional Melanoma Metastases: A Possible Variant of Locus Minoris Resistentiae.
    Donaldson M; Owen JL; Choi JN
    JAMA Dermatol; 2018 Jul; 154(7):846-847. PubMed ID: 29800007
    [No Abstract]   [Full Text] [Related]  

  • 11. [Treating metastatic melanoma: Risk management].
    Lebbe C; Robert C
    Ann Dermatol Venereol; 2017 Jan; 144(1):3-5. PubMed ID: 28063593
    [No Abstract]   [Full Text] [Related]  

  • 12. Birdshot-like Chorioretinopathy Associated With Pembrolizumab Treatment.
    Acaba-Berrocal LA; Lucio-Alvarez JA; Mashayekhi A; Ho AC; Dunn JP; Shields CL
    JAMA Ophthalmol; 2018 Oct; 136(10):1205-1207. PubMed ID: 30054605
    [No Abstract]   [Full Text] [Related]  

  • 13. Third-line pembrolizumab-induced immune-related interstitial pneumonitis after ipilimumab and nivolumab failure.
    Oya K; Nakamura Y; Fujisawa Y; Endo R; Tanaka R; Ishitsuka Y; Maruyama H; Watanabe R; Okiyama N; Fujimoto M
    Eur J Dermatol; 2018 Feb; 28(1):129-130. PubMed ID: 29400284
    [No Abstract]   [Full Text] [Related]  

  • 14. Antiphospholipid Syndrome Following Pembrolizumab Treatment of Stage IIIB Unresectable Melanoma.
    Sanchez A; Montaudie H; Bory P; Belgodere X; Passeron T; Lacour JP; Picard A
    JAMA Dermatol; 2018 Nov; 154(11):1354-1356. PubMed ID: 30326507
    [No Abstract]   [Full Text] [Related]  

  • 15. A case of ruptured hepatic metastases during pembrolizumab administration for cutaneous malignant melanoma.
    Igari S; Yamamoto M; Kikuchi N; Ohtsuka M; Yamamoto T
    An Bras Dermatol; 2024; 99(3):450-451. PubMed ID: 38307808
    [No Abstract]   [Full Text] [Related]  

  • 16. Checkpoint Inhibitor-Induced Hemorrhagic Gastritis with Pembrolizumab.
    Rao BB; Robertson S; Philpott J
    Am J Gastroenterol; 2019 Feb; 114(2):196. PubMed ID: 30353060
    [No Abstract]   [Full Text] [Related]  

  • 17. Checkpoint inhibitor-induced sarcoid reaction mimicking bone metastases.
    Jespersen H; Bjursten S; Ny L; Levin M
    Lancet Oncol; 2018 Jun; 19(6):e327. PubMed ID: 29893264
    [No Abstract]   [Full Text] [Related]  

  • 18. Vitiligo Repigmentation with Melanoma Progression During Pembrolizumab Treatment.
    Nardin C; Pelletier F; Puzenat E; Aubin F
    Acta Derm Venereol; 2019 Sep; 99(10):913-914. PubMed ID: 31017249
    [No Abstract]   [Full Text] [Related]  

  • 19. Hypothyroid ataxia complicating monoclonal antibody therapy.
    Badran A; Moran C; Coles AJ
    Pract Neurol; 2017 Dec; 17(6):482-484. PubMed ID: 28778931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pembrolizumab (Keytruda°) and metastatic or inoperable melanoma.
    Prescrire Int; 2017 May; 26(182):118-119. PubMed ID: 30730667
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.